MENU
GILD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Gilead Sciences (GILD) Earnings Date & Reports

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

GILD is expected to report earnings to fall 16.08% to $2.14 per share on February 04

Gilead Sciences GILD Stock Earnings Reports
Q4'26
Est.
$2.14
Q3'26
Beat
by $0.38
Q2'26
Beat
by $0.56
Q1'26
Beat
by $0.13
Q4'25
Beat
by $0.01
The last earnings report on October 29 showed earnings per share of $2.55, beating the estimate of $2.17. With 2.81M shares outstanding, the current market capitalization sits at 206.94B.
A.I.Advisor
Oct 29, 2026

Gilead Sciences (GILD) Third Quarter 2026 Earnings Recap: HIV Strength Powers a Surprising Quarter

Key Takeaways

  • Total revenue reached $8.3 billion, up 6.8% year over year and above the roughly $7.81 billion consensus estimate.
  • Non-GAAP (adjusted) diluted earnings per share came in at $2.55, a 16.2% beat versus the approximately $2.19 consensus, and up 3% from $2.47 a year ago.
  • GAAP diluted EPS fell to $1.94 from $2.43, pressured by net losses from equity securities and higher operating expenses.
  • Gilead's HIV franchise grew 18% year over year, while HIV prevention sales nearly doubled, driving what management called its strongest base-business growth in more than a decade.
  • The company raised its full-year 2026 product sales guidance to a range of $31.0 billion to $31.3 billion.
  • For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated analysis pages.
  • Discover automated trading ideas and market opportunities with Trending AI Robots.

Earnings Context and Why It Matters

Gilead Sciences is a biopharmaceutical leader best known for its HIV franchise, anchored by Biktarvy and Descovy, alongside a growing oncology and inflammation portfolio. This third-quarter report carries outsized weight because it tests whether the company can sustain durable growth beyond its mature HIV base. Investors are watching closely for momentum in newer products such as Trodelvy and Livdelzi, as well as the trajectory of HIV prevention. The quarter also arrived amid rising scrutiny of drug pricing, with the Centers for Medicare and Medicaid Services having finalized a Maximum Fair Price for Biktarvy that takes effect in 2028. Strong execution here offers a clearer read on Gilead's long-term diversification story.

Reported Results

For the third quarter of 2026, ended September 30, Gilead reported total revenue of $8.3 billion, a 6.8% increase from $7.77 billion a year earlier and above the roughly $7.81 billion Wall Street consensus. Product sales rose 13% to $8.29 billion, and excluding the COVID-19 treatment Veklury, product sales climbed 16% year over year. GAAP diluted EPS declined to $1.94 from $2.43, reflecting net losses from equity securities and higher operating costs, while non-GAAP diluted EPS rose 3% to $2.55 from $2.47.

The HIV franchise grew 18% to about $6.2 billion, with prevention sales nearly doubling. Biktarvy sales were roughly flat at about $4.1 billion, while Trodelvy sales rose 42% to an approximately $2 billion annual run rate. Product gross margin improved to 81.0% from 78.6%. Gilead raised full-year 2026 product sales guidance to $31.0 billion to $31.3 billion, though it widened its non-GAAP EPS outlook to a loss of $1.20 to $0.85 per share, driven largely by acquisition-related and other non-cash items.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like Gilead, the AI Screener can streamline the search for comparable setups across the healthcare sector.

Market Reaction and Investor Sentiment

Gilead shares ended the regular session up 4.0% at $165.61 ahead of the release, then added roughly 1.8% in after-hours trading as investors digested the top- and bottom-line beats. The market appeared to reward the 6.3% revenue beat and the 16.2% non-GAAP EPS beat, as well as the upward revision to full-year product sales guidance. Still, sentiment remains tempered by the wider full-year non-GAAP loss forecast and the near-flat performance of Biktarvy, the company's single largest product. Net-net, the reaction suggests investors are focusing on the accelerating base-business growth rather than the near-term accounting headwinds.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching several catalysts tied to Gilead's diversification strategy. The company expects to file its investigational once-weekly oral HIV regimen, ISL/LEN, before year-end, and a potential approval decision for the cell therapy anito-cel is expected around the end of 2026. These pipeline milestones could meaningfully shape the company's longer-term growth narrative beyond Biktarvy.

In inflammation, Gilead plans to advance emvistegrast into Phase 3 studies for ulcerative colitis in 2027, backed by positive Phase 2 data. The company has also broadened its pipeline through acquisitions, including an oral IL-23 receptor inhibitor program, signaling continued investment in a third strategic therapeutic area alongside HIV and oncology.

On the policy front, the finalized Maximum Fair Price for Biktarvy under Medicare will begin affecting revenue on January 1, 2028, creating a medium-term headwind to monitor. Meanwhile, investors should track whether HIV prevention products such as Yeztugo and Descovy for PrEP (pre-exposure prophylaxis) sustain their rapid uptake, and whether Trodelvy maintains its momentum across breast cancer indications. Margin trends and the pace of operating-expense growth will also remain important signals of disciplined execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutic products and treatments for life threatening diseases

Industry PharmaceuticalsMajor

Industry
Biotechnology
Address
333 Lakeside Drive
Phone
+1 650 574-3000
Employees
17000
Web
https://www.gilead.com